India Pharma Outlook Team | Thursday, 25 September 2025
Ipca Laboratories has made an accomplishment by signing a Technology Transfer and Joint Development Agreement that is definite with BioSimilar Sciences PR LLC (BSS). This is for the quickening of the development process, and the eventual provision of cheap biological drugs for the treatment of cancer and other autoimmune diseases.
Ipca as per the agreement will hand over the clinical manufacture, clinical development, and commercial supply of the next-generation monoclonal antibody biosimilar that targets oncology and inflammatory disorders to the sterile manufacturing campus of BSS in Aguadilla, Puerto Rico, which is equipped with modern facilities. The 200,000 square-foot facility is designed to meet the requirements of global regulatory standards and is very close to both the U.S. and international markets.
Cancer and autoimmune diseases as the major sources of demand for biologics of high quality, the principal objective of this alliance is to fill in the price differential gap while guaranteeing the extendibility and the trustworthiness of the supply.
Also Read: Global Heart Hub, Novartis Push Awareness of Elevated Lp(a)
On this, a spokesperson for Ipca said that the agreement is integral to the long-term plan of the company to leverage global partnerships and, thereby, bring innovative biologics to emerging and regulated markets. BSS responded by stating that its aim is to provide top-quality clinical and commercial biologics manufacturing services in Puerto Rico.
Such a strategic alliance is a testament to the increasing role of global collaborations in the biosimilar field, not only facilitating wider access to life-saving therapies but also fortifying the monoclonal antibodies portfolio targeted at affordability all over the world.
